AIOS European pharmacy distribution playbook

Buying Bolt turned AIOS from a business exposed to a US compounding shutdown into a cross border growth machine built on licensed pharmacy distribution. In Britain, the key asset was not a new drug or better clinical protocol, it was a regulated online pharmacy that could dispense branded Wegovy and Mounjaro into a large cash pay market where NHS access stayed tight, prices were visible, and customer acquisition could be scaled with consumer marketing.

• The UK market worked because AIOS could swap from selling cheap compounded GLP-1s in the US to selling genuine branded pens in a country where private patients already buy weekly treatment online. Bolt listed GLP-1 plans in a roughly £25 to £42 per week range, matching the revenue per patient implied by AIOS's later scale.
  1 boltpharmacy 2 sacra
• The playbook was simple and concrete. Run paid ads, send patients into a short online eligibility flow, route approvals through a prescriber, ship medication from the pharmacy, then manage refills and dose increases in the same product. That is the same consumer funnel Fella had already learned in the US, now attached to a legal branded drug channel.
  2 sacra 3 sacra
• Bolt also gave AIOS a price wedge against incumbents. AIOS positioned Bolt as the cheapest regulated branded source in Britain, below pharmacies such as Boots and Numan, while larger rivals chose different angles, with Ro leaning on assured Wegovy supply and Hims & Hers entering the UK by acquiring ZAVA for licensed local infrastructure.
  2 sacra 4 sacra 5 boots 6 hims

This points toward a European roll up strategy where the scarce asset is local pharmacy and clinical licensing, not demand generation. If AIOS can keep buying regulated distribution in new countries, it can keep replaying the same acquisition funnel on top of each market, then capture more margin later when generic semaglutide opens up.